Condition: Glioma, Malignant · Sponsor: Darell Bigner
This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
This description comes directly from the study's public registry record.
Annick Desjardins, MD. FRCPC · 919-684-5301 · dukebrain1@dm.duke.edu
Stevie Threatt · 919-684-5301 · dukebrain1@dm.duke.edu
Always discuss trial participation with your own doctor first.
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04547777